I agree that this site is using cookies. You can find further informations here.
X
Thigpen, J. Tate
86  results:
Search for persons X
?
1

Factors associated with deciding between risk-reducing salp..:

Mai, Phuong L ; Piedmonte, Marion ; Han, Paul K...
Gynecologic Oncology.  145 (2017)  1 - p. 122-129 , 2017
Link: https://doi.org/10.1016/..
 
?
2

A stratified randomized double-blind phase II trial of cele..:

Rader, Janet S. ; Sill, Michael W. ; Beumer, Jan H....
Gynecologic Oncology.  145 (2017)  2 - p. 291-297 , 2017
Link: https://doi.org/10.1016/..
 
?
3

A phase II study of paclitaxel for the treatment of ovarian..:

Burton, Elizabeth R. ; Brady, Mark ; Homesley, Howard D....
Gynecologic Oncology.  140 (2016)  1 - p. 48-52 , 2016
Link: https://doi.org/10.1016/..
 
?
4

Is age a prognostic biomarker for survival among women with..:

Moore, Kathleen N. ; Java, James J. ; Slaughter, Katrina N....
Gynecologic Oncology.  143 (2016)  2 - p. 294-301 , 2016
Link: https://doi.org/10.1016/..
 
?
5

Contemporary phase III clinical trial endpoints in advanced..:

Tate Thigpen, J.
Gynecologic Oncology.  136 (2015)  1 - p. 121-129 , 2015
Link: https://doi.org/10.1016/..
 
?
6

Ovarian cancer clinical trial endpoints: Society of Gynecol..:

Herzog, Thomas J. ; Armstrong, Deborah K. ; Brady, Mark F....
Gynecologic Oncology.  132 (2014)  1 - p. 8-17 , 2014
Link: https://doi.org/10.1016/..
 
?
7

Association of number of positive nodes and cervical stroma..:

Tewari, Krishnansu S. ; Filiaci, Virginia L. ; Spirtos, Nick M....
Gynecologic Oncology.  125 (2012)  1 - p. 87-93 , 2012
Link: https://doi.org/10.1016/..
 
?
8

Cytokine use and survival in the first-line treatment of ov..:

Stehman, Frederick B. ; Brady, Mark F. ; Thigpen, J. Tate..
Gynecologic Oncology.  127 (2012)  3 - p. 495-501 , 2012
Link: https://doi.org/10.1016/..
 
?
9

CON: Secondary Surgical Debulking is Not an Acceptable Opti..:

Thigpen, J. Tate
Clinical Ovarian Cancer.  4 (2011)  2 - p. 80-82 , 2011
Link: https://doi.org/10.1016/..
 
?
10

Phase II study of cisplatin plus cetuximab in advanced, rec..:

Farley, John ; Sill, Michael W. ; Birrer, Michael...
Gynecologic Oncology.  121 (2011)  2 - p. 303-308 , 2011
Link: https://doi.org/10.1016/..
 
?
11

CON: Patients With Metastatic/Recurrent Cervical Cancer Sho..:

Thigpen, J. Tate
Clinical Ovarian Cancer.  4 (2011)  2 - p. 94-96 , 2011
Link: https://doi.org/10.1016/..
 
?
12

PRO: Therapy for a Patient With Platinum–Resistant/Refracto..:

Thigpen, J. Tate
Clinical Ovarian Cancer.  4 (2011)  2 - p. 54-56 , 2011
Link: https://doi.org/10.1016/..
 
?
13

CON: Systemic Therapy for All Endometrial Carcinomas Should..:

Thigpen, J. Tate
Clinical Ovarian Cancer.  4 (2011)  2 - p. 101-105 , 2011
Link: https://doi.org/10.1016/..
 
?
14

PRO: Patients With Endometrial Carcinoma Involving Extraute..:

Thigpen, J. Tate
Clinical Ovarian Cancer.  4 (2011)  2 - p. 62-65 , 2011
Link: https://doi.org/10.1016/..
 
?
15

Age as a prognostic factor in ovarian carcinoma: The gyneco..:

Thigpen, Tate ; Brady, Mark F. ; Omura, George A....
Cancer.  71 (2010)  S2 - p. 606-614 , 2010
Link: https://doi.org/10.1002/..
 
1-15